The recently FDA-cleared device is designed for minimally invasive treatment through radiofrequency ablation, using heat to target specific nerves and block pain signals from reaching the brain. According to a news release. it’s the first Abbott-developed RF ablation device and has U.S. and European approval.
Dr. Jason Pope of the Santa Rosa, Calif. Evolve Restoration Center said in the release that Abbott’s IonicRF is an “advanced device platform” with promising aspects such as effectiveness in targeting pain in several discrete areas of the body.
“Most people who are candidates for radiofrequency ablation have tried other therapies, such as medications and injections, with limited success,” Abbott VP of neuromodulation Keith Boettiger said. “As a result, they are now seeking an alternative solution that does not require surgery or the use of opioid medication. We are proud to be able to provide the first Abbott-designed radiofrequency ablation device engineered to deliver safe and effective pain management.
“This is another example of our focus on widening the breadth of our neuromodulation portfolio and keeping patients central to everything we do at Abbott.”